Trending...
- Spokane City Council Members Introduce "Immigration Enforcement Free Zones"
- Welfare Check Leads To Domestic Violence Arrest; Guns and Drugs Recovered At North Spokane Apartment
- New Threat Management Workshop Brings Hands-On BTAM Training to Spokane Valley
SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global myeloproliferative neoplasm drugs market is estimated to be valued at US$ 8,379.5 million in 2020 and is expected to exhibit a CAGR of 3.9% over the forecast period (2020-2027).
Key Trends and Analysis:
The increasing incidence of myeloproliferative neoplasm is expected to drive growth of the global myeloproliferative neoplasm drugs market over the forecast period. According to the National Organization for Rare Disorders (NORD) 2020, men are more likely to be affected than women with polycythemia vera and this disorder is expected to affect around two people per 100,000 in the general population globally.
Moreover, the increasing number of pipeline products for the treatment of myeloproliferative neoplasm is expected to fuel growth of the global myeloproliferative neoplasm drugs market in the near future. For instance, on January 7, 2021, PharmaEssentia Corporation, a company focusing on research and development in biopharmaceutical industry, announced the initiation of investigational study phase 3 pivotal clinical trial of SURPASS ET, [Ropeginterferon Alfa-2b (P1101)]. SURPASS ET is a novel mono-pegylated proline interferon under evaluation for the treatment of the essential thrombocythemia (ET) type of myeloproliferative neoplasm (MPNs).
Among regions, North America is expected to register highest growth rate, owing to increasing number of pipeline products for the treatment of myeloproliferative neoplasm. For instance, in December 2020, AbbVie Inc. announced new data from the Phase 2 CAPTIVATE (PCYC-1142) clinical trial, evaluating IMBRUVICA (ibrutinib) in combination with VENCLEXTA/VENCLYXTO (venetoclax) in previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), during an oral presentation session at the virtual 2020 American Society of Hematology (ASH) Annual Meeting.
More on Washingtoner
Request Sample Copy of this Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/930
Key Market Takeaways:
The global myeloproliferative neoplasm drugs market is expected to exhibit a CAGR of 3.9% over the forecast period, as key players are focusing on strategies such as mergers and acquisitions in order to strengthen their position in the market. For Instance, in February 2020, F. Hoffmann-La Roche AG completely acquired Promedior, Inc., a clinical stage biotechnology company. As a result of this acquisition, F. Hoffmann-La Roche AG would obtain full rights to Promedior's entire portfolio of molecules for serious fibrotic diseases, including PRM-151.
Competitive Landscape:
Key players operating in the global myeloproliferative neoplasm drugs market include Novartis International AG, PharmaEssentia Corporation, Bristol - Myers Squibb, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Incyte, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Gamida Cell, Sierra Oncology, Inc., CTI BioPharma Corp., Imago BioSciences, AbbVie Inc., and Constellation Pharmaceuticals
Buy-Now this Research Report for detailed market insights @
https://www.coherentmarketinsights.com/insight/buy-now/930
Market Segmentation:
Related Market Intelligence Reports:
More on Washingtoner
Urinary Incontinence Treatment Drugs Market, by Incontinence Type (Urge Incontinence, Stress Incontinence, Over-flow Incontinence, Mixed Incontinence, and Other Type), by Drug Class (Anticholinergic/Antispasmodic Agents, Skeletal Muscle Relaxants, Antidepressants, Alpha Blockers, Topical Estrogens, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
Read-more: https://www.coherentmarketinsights.com/market-insight/urinary-incontinence-treatment-drugs-market-4400
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.
Key Trends and Analysis:
The increasing incidence of myeloproliferative neoplasm is expected to drive growth of the global myeloproliferative neoplasm drugs market over the forecast period. According to the National Organization for Rare Disorders (NORD) 2020, men are more likely to be affected than women with polycythemia vera and this disorder is expected to affect around two people per 100,000 in the general population globally.
Moreover, the increasing number of pipeline products for the treatment of myeloproliferative neoplasm is expected to fuel growth of the global myeloproliferative neoplasm drugs market in the near future. For instance, on January 7, 2021, PharmaEssentia Corporation, a company focusing on research and development in biopharmaceutical industry, announced the initiation of investigational study phase 3 pivotal clinical trial of SURPASS ET, [Ropeginterferon Alfa-2b (P1101)]. SURPASS ET is a novel mono-pegylated proline interferon under evaluation for the treatment of the essential thrombocythemia (ET) type of myeloproliferative neoplasm (MPNs).
Among regions, North America is expected to register highest growth rate, owing to increasing number of pipeline products for the treatment of myeloproliferative neoplasm. For instance, in December 2020, AbbVie Inc. announced new data from the Phase 2 CAPTIVATE (PCYC-1142) clinical trial, evaluating IMBRUVICA (ibrutinib) in combination with VENCLEXTA/VENCLYXTO (venetoclax) in previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), during an oral presentation session at the virtual 2020 American Society of Hematology (ASH) Annual Meeting.
More on Washingtoner
- HBMHCW Expande Infraestructura de Cumplimiento para Argentina mientras América Latina Supera $1.5 Billones en Volumen Cripto
- Norisia Launches AI Formulated Luxury Multivitamin to Transform Daily Wellness in the UK
- City of Tacoma Invites Community Input on Proposals to Modernize Housing, Zoning, and Land Use Codes for 2026
- Tacoma: Mayor Anders Ibsen to Deliver First State of the City Address on March 4
- Jacob Emrani's Annual "Supper Bowl" Expected To Donate Thousands Of Meals
Request Sample Copy of this Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/930
Key Market Takeaways:
The global myeloproliferative neoplasm drugs market is expected to exhibit a CAGR of 3.9% over the forecast period, as key players are focusing on strategies such as mergers and acquisitions in order to strengthen their position in the market. For Instance, in February 2020, F. Hoffmann-La Roche AG completely acquired Promedior, Inc., a clinical stage biotechnology company. As a result of this acquisition, F. Hoffmann-La Roche AG would obtain full rights to Promedior's entire portfolio of molecules for serious fibrotic diseases, including PRM-151.
Competitive Landscape:
Key players operating in the global myeloproliferative neoplasm drugs market include Novartis International AG, PharmaEssentia Corporation, Bristol - Myers Squibb, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Incyte, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Gamida Cell, Sierra Oncology, Inc., CTI BioPharma Corp., Imago BioSciences, AbbVie Inc., and Constellation Pharmaceuticals
Buy-Now this Research Report for detailed market insights @
https://www.coherentmarketinsights.com/insight/buy-now/930
Market Segmentation:
- Global Myeloproliferative Neoplasm Drugs Market, By Drug Class:
- Demethylation Agents
- Tyrosine kinase Inhibitor
- Multikinase Inhibitors
- JAK2 Inhibitor
- Others
- Global Myeloproliferative Neoplasm Drugs Market, By Indication:
- Ph+ Chronic myelogenous leukemia (CML)
- Ph- Myeloproliferative Neoplasms (MPNs)
- Myelofibrosis (MF)
- Polycythemia Vera (PV)
- Essential thrombocythemia (ET)
- Global Myeloproliferative Neoplasm Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Myeloproliferative Neoplasm Drugs Market, By Region:
- North America
- By Country:
- U.S.
- Canada
- By Country:
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country:
- Europe
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Country:
- Asia Pacific
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country:
- Middle East
- By Country/Region:
- GCC
- Israel
- Rest of Middle East
- By Country/Region:
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Country/Region:
- North America
Related Market Intelligence Reports:
More on Washingtoner
- NASA / Glenn Research Center Collaboration to Help Meet Rising Demand for Space Energy Beaming Tech / CIGS PV Modules from Ascent Solar: NAS DAQ: ASTI
- When Interpretation Becomes Conversation: Rethinking Engagement in the Museum Age
- Half of Finnish Online Gambling Expenditure Now Flows to Offshore Instant Casinos as License Applications Open March 1, 2026
- RTC Communications Completes Next Level Connect Fiber Expansion Bringing Multi-Gig Broadband to West Boggs Community
- EPP Pricing Platform announces leadership transition to support long-term growth and continuity
Urinary Incontinence Treatment Drugs Market, by Incontinence Type (Urge Incontinence, Stress Incontinence, Over-flow Incontinence, Mixed Incontinence, and Other Type), by Drug Class (Anticholinergic/Antispasmodic Agents, Skeletal Muscle Relaxants, Antidepressants, Alpha Blockers, Topical Estrogens, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
Read-more: https://www.coherentmarketinsights.com/market-insight/urinary-incontinence-treatment-drugs-market-4400
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.
0 Comments
Latest on Washingtoner
- Sleep Basil Curates a Clearer Brooklyn Bedding Experience for Performance-Minded Denver Sleepers
- Spokane City Council Members Introduce "Immigration Enforcement Free Zones"
- Spokane: Mayor Brown Calls on Congress to Extend Temporary Protected Status for Haitian Community Members
- Nevada Man Launches Nationwide Animal Abuse Registry
- New Threat Management Workshop Brings Hands-On BTAM Training to Spokane Valley
- Star-powered Kappa Takeover Weekend Returns to the DMV June 18- 21, 2026, Hosted By Comedian Joe Clair W/ Dj Quick Silva (the Party Kingpin)
- Tacoma: Homicide Investigation – 1200 Block of South I Street
- Welfare Check Leads To Domestic Violence Arrest; Guns and Drugs Recovered At North Spokane Apartment
- Scoop Social Co. Wins The Knot and WeddingWire Awards as Brand Expands Nationwide
- Denise Murphy Lenci Promoted to Century Fasteners Corp. – General Manager, Northeast Sales
- TiNY Puts Real Pets on the Payroll for New PetArmor Campaign
- P‑Wave Classics Launches Definitive New Edition of Hannah Webster Foster's The Coquette
- Strategic Expansion with 3 New Alliances — Jefferson Beach Yacht Sales, CFR YS & flyExclusive Incentive Partnership: Off The Hook YS: (N Y S E: OTH)
- Super League (N A S D A Q: SLE) Advances AI-Driven Playable Media with AdArcade, Solsten, and Meta-Stadiums Partnerships, Plus Roblox Theatre Launch
- purelyIV Expands Concierge Wellness Platform with New IV Therapies, Memberships, and Digital Experience
- CCHR: Europe Rejects Forced Psychiatry—Landmark Vote Declares Coercive Practices Incompatible with Human Rights
- Crossroads4Hope Kicks Off Its 25th Year of Caring with the Launch of Free Breast and Colorectal Cancer Resources for Patients and Families Nationwide
- OpenSSL Corporation Advisory Committees' Elections 2026: Voting Now Open
- Good Vibes Club and Instant IP Forge Strategic Partnership to Secure IP Brand Value in a Booming Digital Economy
- Inkdnylon Simplifies Digitizing and Vector Art Nationwide With Clear Pricing and Guided File Support